February 5, 2024


Vaccine company Zhengye Biotechnology files for US$20 million IPO




Zhengye Biotechnology, which specialises in livestock vaccines, has filed for a proposed US$20 million US initial public offering, Seeking Alpha reported recently.


The company didn't specify any terms in its SEC filing, but indicated it was interested in raising around US$20 million.


US Tiger Securities is serving as bookrunner. The company hopes to list its ordinary shares on Nasdaq under the symbol, ZYBT.


Incorporated in the Cayman Islands, Zhengye operates primarily through a subsidiary in China. The company develops and markets veterinary vaccines for swine, goats, sheep, cattle, poultry and dogs.


The products are sold in China, Egypt, Vietnam and Pakistan.


- Seeking Alpha